[
  {
    "ts": null,
    "headline": "HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline",
    "summary": "Gilead Sciences' HIV therapies and liver drug Livdelzi drive Q3 revenue growth, offsetting weaker Veklury and Cell Therapy sales.",
    "url": "https://finnhub.io/api/news?id=df8fc6ca9557d40bff3c2e4b1899ee9f0ab7b9c3f7a6a0a786b94b7409c1bfb9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762263480,
      "headline": "HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline",
      "id": 137312375,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences' HIV therapies and liver drug Livdelzi drive Q3 revenue growth, offsetting weaker Veklury and Cell Therapy sales.",
      "url": "https://finnhub.io/api/news?id=df8fc6ca9557d40bff3c2e4b1899ee9f0ab7b9c3f7a6a0a786b94b7409c1bfb9"
    }
  }
]